Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 8,371 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: serum sample Clear all
Completed Phase 4 Interventional Results available

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

NCT01511315
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 17, 2026, 1:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

NCT00726180
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab (Herceptin®)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Oct 17, 2026, 1:34 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety Study of Rituximab (Rituxan®) in Chronic Urticaria

NCT00216762
View directory record Official record
Conditions
Urticaria
Interventions
Rituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

NCT00084656
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
ipilimumab, Tyrosinase/gp100/MART-1 Peptides
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 17, 2026, 1:34 PM EDT
Recruiting No phase listed Observational

Serum Inflammatory Protein Concentration During Dental Treatment

NCT07468929
View directory record Official record
Conditions
Periodontal Disease, Periodontal Surgery
Interventions
Blood samples for inflammatory markers, periodontal surgery, Periodontal maintenance, Non-surgical deep cleaning
Other · Procedure
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 1:34 PM EDT
Active, not recruiting Phase 2 Interventional

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

NCT04803877
View directory record Official record
Conditions
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Osteosarcoma Metastatic
Interventions
Regorafenib 40 MG, Regorafenib 20MG, Nivolumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
5 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00504075
View directory record Official record
Conditions
Chronic Idiopathic Thrombocytopenic Purpura
Interventions
Gammaplex, intravenous immunoglobulin
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Orange City, Florida • Chicago, Illinois • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

NCT02569242
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Nivolumab, Docetaxel/Paclitaxel
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
20 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Gilbert, Arizona • Washington D.C., District of Columbia • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

NCT02660580
View directory record Official record
Conditions
Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
MSB11022, Humira®
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 17, 2026, 1:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Investigation for the Preview® hCG Urine/Serum Combo Pregnancy Test

NCT04207554
View directory record Official record
Conditions
Pregnancy
Interventions
Test Device-Strip Format, Test Device-Cassette Format, Predicate Device
Device
Lead sponsor
Guangzhou Wondfo Biotech Co., Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
6
States / cities
Garden Grove, California • Huntington Park, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 17, 2026, 1:34 PM EDT
Recruiting Phase 2 Interventional

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

NCT06954805
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell
Interventions
Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq
Drug · Device
Lead sponsor
Jennifer Amengual
Other
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 17, 2026, 1:34 PM EDT
Not listed Phase 2 Interventional Results available

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

NCT04117945
View directory record Official record
Conditions
BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Cetuximab, Irinotecan, Panitumumab, Regorafenib
Biological · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

NCT02059239
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Carmustine, Etoposide, Melphalan, Cytarabine, Alemtuzumab, Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Rituximab
Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

NCT00369681
View directory record Official record
Conditions
Lymphoma
Interventions
Bleomycin, Rituximab, Dacarbazine, Doxorubicin, Vinblastine
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Duarte, California • Iowa City, Iowa • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

NCT02924883
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Atezolizumab, Trastuzumab emtansine, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation

NCT00214266
View directory record Official record
Conditions
Renal Transplantation
Interventions
Campath 1H®, Rituximab, mycophenolate mofetil
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma

NCT00891839
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Bendamustine, Rituximab
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
11
States / cities
Fountain Valley, California • Los Angeles, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 17, 2026, 1:34 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 17, 2026, 1:34 PM EDT
Terminated Phase 1 Interventional

Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

NCT04203875
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
Orencia® (Abatacept)
Drug
Lead sponsor
Stuart Knechtle, M.D.
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Oct 17, 2026, 1:34 PM EDT
Terminated Phase 1 Interventional

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

NCT02833701
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Ascorbic Acid, Bevacizumab, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Dietary Supplement · Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 17, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT05774639
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab Injection, Xolair Prefilled Syringe
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 17, 2026, 1:34 PM EDT
Not listed Phase 4 Interventional

Denosumab Administration After Spinal Cord Injury

NCT01983475
View directory record Official record
Conditions
Osteoporosis, Spinal Cord Injury
Interventions
Denosumab, Placebo (identical Denosumab volume of normal saline)
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 17, 2026, 1:34 PM EDT